Zygmuntowicz Aleksandra, Burmańczuk Artur, Markiewicz Włodzimierz
Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 13, 10-718 Olsztyn, Poland.
Sub-Department of Pharmacology, Toxicology and Environmental Protection, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, 12 Akademicka St., 20-950 Lublin, Poland.
Animals (Basel). 2020 Dec 9;10(12):2343. doi: 10.3390/ani10122343.
Definitions of biological medicinal products (BMPs) vary depending on the source. BMPs are manufactured using complex biological/biotechnological processes involving living cell lines, tissues and organisms such as microorganisms, plants, humans and even animals. Advances in modern biotechnological methods and genetic engineering have made it possible to search for new drugs with a targeted effect and simultaneous reduction of adverse effects, which has resulted in BMPs dynamically increasing their share in the pharmaceutical market. Currently, these drugs are widely used in the treatment of many human diseases, but an increasing number of drugs of this group are also being used in the treatment of animals, mainly in dermatology, rheumatology and oncology. This article presents the current state of knowledge in the field of biological medicinal products used in animal therapy.
生物药品(BMPs)的定义因来源而异。BMPs是通过复杂的生物/生物技术过程生产的,这些过程涉及活细胞系、组织和生物体,如微生物、植物、人类甚至动物。现代生物技术方法和基因工程的进步使得寻找具有靶向作用且能同时减少不良反应的新药成为可能,这导致BMPs在制药市场中的份额不断动态增加。目前,这些药物广泛用于治疗多种人类疾病,但这类药物也越来越多地用于治疗动物,主要用于皮肤科、风湿病学和肿瘤学领域。本文介绍了用于动物治疗的生物药品领域的当前知识状况。